Allergic bronchopulmonary aspergillosis.
Allergic bronchopulmonary aspergillosis (ABPA) is caused by an exaggerated T(H)2 response to the ubiquitous mold Aspergillus fumigatus. ABPA develops in a small fraction of patients with cystic fibrosis and asthma, suggesting that intrinsic host defects play a major role in disease susceptibility. This article reviews current understanding of the immunopathology, clinical and laboratory findings, and diagnosis and management of ABPA. It highlights clinical and laboratory clues to differentiate ABPA from cystic fibrosis and asthma, which are challenging given clinical and serologic similarities. A practical diagnostic algorithm and management scheme to aid in the treatment of these patients is outlined.
Division of Pulmonary, Critical Care, Allergy & Sleep Medicine, Medical University of South Carolina, Charleston, 29425, USA.
Sonia N
SN
Bains
Marc A
MA
Judson
D001229:Aspergillosis, Allergic Bronchopulmonary / Q000175:diagnosis / Q000276:immunology / Q000628:therapy; D001249:Asthma / Q000150:complications; D003550:Cystic Fibrosis / Q000150:complications; D003937:Diagnosis, Differential; D006801:Humans